What's happened to elinogrel? Novartis misses former hot prospect off blockbuster list
This article was originally published in Scrip
Novartis appears to be re-assessing the potential of the antiplatelet candidate elinogrel that it licensed for up to $575 million from Portola Pharmaceuticals in 2009. It was conspicuous by its absence from a sample list of seven potential blockbusters currently in the Swiss major's pipeline at its second-quarter results presentation yesterday.